MicroRNA-483 amelioration of experimental pulmonary hypertension

ABSTRACT: Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit. Lower levels of miR-483 were found in serum from patients with idiopathic pulmonary arterial hypertension (IPAH), particularly these with more severe disease. RNA-seq and bioinformatic analyses showed that miR-483 targets several PAH-related genes, including transforming growth factor-? (TGF-?), TGF-? receptor 2 (TGFBR2), ?-catenin, connective tissue growth factor (CTGF), interleukin-1? (IL-1?), and endothelin-1 (ET-1). Overexpression of miR-483 in ECs inhibited inflammatory and fibrogenic responses, revealed by the decreased expression of TGF-?, TGFBR2, ?-catenin, CTGF, IL-1?, and ET-1. In contrast, inhibition

SUBMITTER: Jin Zhang 

PROVIDER: S-SCDT-EMM-2019-11303 | biostudies-other |

REPOSITORIES: biostudies-other